Skip to main content

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

Written by Customer Service on . Posted in Public Companies.

Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first time

ZUG, Switzerland, Feb. 10, 2026 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced the acceptance of six abstracts for poster presentation, three of which will be presented during the Featured Poster session, at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting, to be held from February 27-March 2, 2026, in Philadelphia, PA.

“Following the announcement of topline RAPIDe-3 data in December of last year, the AAAAI Annual Meeting provides Pharvaris with the first opportunity to share the positive study results with the broader medical community at a large scientific congress,” said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris. “We will also be presenting final data from the open-label portion of CHAPTER-1, the Phase 2 study of deucrictibant for prophylaxis of HAE attacks, and pharmacokinetic data of deucrictibant extended-release tablet, which is being used in the pivotal Phase 3 study of deucrictibant for long-term prophylaxis of HAE attacks, CHAPTER-3. Final efficacy and safety results from approximately three years of deucrictibant treatment from CHAPTER-1 and the data providing further evidence of an optimized extended-release formulation provide strong foundations in advance of the results of CHAPTER-3, topline data from which is anticipated in the third quarter of this year. Additionally, we will be presenting on-demand endpoint validation findings, as well as results from our novel kinin biomarker assay.”

Details of the presentations are as follows:

  • Title: A Novel Kinin Biomarker Assay for Characterization of Different Types of Bradykinin-Mediated Angioedema
    Presenter: Evangelia Pardali, Ph.D.
    Poster Number: 078
    Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST
  • Title: Content Validity of the Angioedema syMptom Rating scAle (AMRA) to Assess Symptoms of Hereditary Angioedema Attacks
    Presenter: Teresa Caballero, M.D., Ph.D.
    Poster Number: 154
    Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST
  • Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
    Presenter: Michael E. Manning, M.D.
    Poster Number: 159
    Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST
  • Title: Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Study
    Presenter: Marc A. Riedl, M.D., M.S.
    Featured Poster Number: 831
    Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
    Presenter: John Anderson, M.D.
    Featured Poster Number: 832
    Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST
  • Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
    Presenter: Zhi-Yi Zhang, Ph.D.
    Featured Poster Number: 834
    Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST

The abstracts are available to view in an online supplement to The Journal of Allergy and Clinical Immunology (JACI) at jacionline.org.

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing global marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit https://pharvaris.com/.

CONTACT: Contact
Maggie Beller
Executive Director, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.